Prostate Cancer - Results from #19080

#GU15 - Poster: Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302 February 26, 2015

#GU15 - Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302 - Session Highlights February 26, 2015

#GU15 - Quantitative total bone imaging (QTBI) in patients with metastatic castration-resistant prostate cancer (CRPC) using NaF PET/CT - Session Highlights February 26, 2015

#GU15 - AR-based biomarker association with response to abiraterone in mCRPC - Session Highlights February 26, 2015

#GU15 - Antigen-specific immune responses through 24 months in the STAND trial: A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T and androgen deprivation therapy in biochemically-recurrent prostate cancer - Session Highlights February 26, 2015

#GU15 - Assessment of corticosteroid-associated adverse events with long-term exposure to low-dose prednisone given with abiraterone acetate in mCRPC - Session Highlights February 26, 2015

Risk of cardiovascular events with degarelix versus leuprolide after biochemical relapse of prostate cancer: Exploratory analysis of a randomized controlled trial - Session Highlights February 26, 2015

#GU15 - Increase in higher risk prostate cancer cases following new screening recommendation by the US Preventive Services Task Force (USPSTF) - Session Highlights February 26, 2015

#GU15 - Early radiation response between GnRH agonist versus antagonist combined with radiotherapy in high-risk prostate cancer - Session Highlights February 26, 2015

#GU15 - Impact of CCP test on personalizing treatment decisions: Results from a prospective registry of newly diagnosed prostate cancer patients - Session Highlights February 26, 2015

#GU15 - Abstract highlights: AR splice variant 7 (AR-V7) and response to taxanes in men with mCRPC - Session Highlights February 26, 2015

#GU15 - Bench to bedside: Androgen resistance - Session Highlights February 26, 2015

#GU15 - Clinical context: Using new imaging modalities to identify early metastatic disease - Session Highlights February 26, 2015

#GU15 - Role of local therapy - Session Highlights February 26, 2015

#GU15 - A multi-institutional prospective trial in the United States confirms the 4K Score accurately identifies men with high-grade prostate cancer - Session Highlights February 26, 2015

#GU15 - Biomarkers for prostate cancer: Why aren’t we using them and where do we go from here? - Session Highlights February 26, 2015

#GU15 - Hormonal therapy: How long is enough? - Session Highlights February 26, 2015

#GU15 - Who can receive shorter-course radiotherapy? Hypofractionation and stereotactic body radiation therapy - Session Highlights February 26, 2015

#GU15 - Individualized treatment decisions for localized prostate cancer: Decision aids and quality of life outcomes - Session Highlights February 26, 2015

Totally extraperitoneal inguinal hernia repair during extraperitoneal laparoscopic radical prostatectomy: Report of a case - Abstract February 26, 2015

Page 955 of 1454